Advertisement

AAPS PharmSciTech

, Volume 5, Issue 3, pp 30–37 | Cite as

A method to determine the incorporation capacity of camptothecin in liposomes

  • Ann Mari Sætern
  • Gøril Eide Flaten
  • Martin Brandl
Article

Abstract

The purpose of this study was to establish a new experimental approach to determine the maximum amount of campothecin (CPT) that can be incorporated in liposomes, and to use this method to compare the CPT-incorporation capacity of various liposome formulations. Small, CPT-saturated liposomes were prepared by dispersing freeze-dried blends of lipids and drug in phosphate buffer, and subsequent probe-sonication. Excess precipitated CPT could be separated from the liposomes by ultra-centrifugation. The small and homogeneous liposome size obtained gave a good and reproducible recovery of liposomes in the supernatant (>80%), whereas the acidic pH (pH 6.0) kept CPT in its hydrophobic lactone form, which is poorly soluble in the buffer. The maximum CPT-incorporation capacity of 12 different liposome formulations was investigated, using the described method, and was found to vary widely. With liposomes made of neutral and anionic phospholipids, the solubili ty of CPT in the buffer was improved by approximately a factor of 10 (from ∼2.7 to 15–50 μg/mL) as compared with buffer. With cationic liposomes containing 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), a maximum CPT-solubilization of ∼100-fold, the buffer solubility was reached, probably owing to an electrostatic interaction between the cationic lipids and the carboxylate-CPT isomer. Increasing DOTAP fractions within egg-phosphatidylcholine (EPC)/DOTAP liposomes reached a CPT-incorporation plateau at ∼20 mol% DOTAP. The presented approach appears suitable to study the incorporation capacity of any drug component within small vesicles as long as the liposome incorporation is high relative to the intrisic water solubility of the drug.

Keywords

liposomes camptothecin drug carriers incorporation DOTAP 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jain A, Sanghvi T, Yalkowsky SH. Liposome formulation of NSC-639829 using halothane as a solvent: a technical note.AAPS PharmSciTech. 2003;4:E52.CrossRefGoogle Scholar
  2. 2.
    Lee K-E, Kim J-J, Yuk H-G, Jang J-Y, Lee S-C. Effect of phase transition temperature of phospholipids on the stability of retinol incorporated into liposomes.J Food Sci. 2003;8:235–238.Google Scholar
  3. 3.
    Engel A, Chatterjee SK, Al-Arifi A, Nuhn P. Influence of spacer length on the agglutination of glycolipid-incorporated liposomes by ConA as model membrane.J Pharm Sci. 2003;92:2229–2235.CrossRefGoogle Scholar
  4. 4.
    Qi XR, Liu MH, Liu HY, Maitani Y, Nagai T. Topical econazole delivery using liposomal gel.STP Pharm Sci. 2003;13:241–245.Google Scholar
  5. 5.
    Rodriguez ME, Awruch J, Dicelio L. Photophysical properties of Zn(II) incorporated into liposomes.J Porphyr Pathalocyanin. 2002;6:122–129.CrossRefGoogle Scholar
  6. 6.
    Socaciu C, Bojarski P, Aberle L, Diehl HA. Different ways to insert carotenoids into liposomes affect structure and dynamics of the bilayer differently.Biophys Chem. 2002;99:1–15.CrossRefGoogle Scholar
  7. 7.
    Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease.Curr Pharm Des. 2002;8:441–454.CrossRefGoogle Scholar
  8. 8.
    Bom D, Curran DP, Zhang J, Zimmer SG, Bevins R, Kruszewski S, et al. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.J Control Release. 2001;74(1–3):325–333.CrossRefGoogle Scholar
  9. 9.
    Lundberg BB. Biologically active camptothecin derivatives for incorporation in o liposome bilayers and lipid emulsions.Anticancer Drug Des. 1998;13:453–461.Google Scholar
  10. 10.
    Sugarman SM, Zou YY, Wasan K, et al. Lipid complexed camptothecin: formulation and initial biodistribution and antitumor activity studies.Cancer Chemother Pharmacol. 1996;37:531–538.CrossRefGoogle Scholar
  11. 11.
    Cortesi R, Esposito E, Maietti A, Menegatti E, Nastruzzi C. Formulation study for the antitumor drug campoothecin: liposomes, micellar solutions and a microemulsion.Int J Pharm. 1997;159:95–103.CrossRefGoogle Scholar
  12. 12.
    Burke TG, Mishra AK, Wani MC, Wall ME. Lipid bilayer partitioning and stability of camptothecin drugs.Biochemistry. 1993;32:5352–5364.CrossRefGoogle Scholar
  13. 13.
    Daoud SS, Fetouh MI, Giovanella BC. Antitumor effect of liposome-incorporated camptothecin in human-malignant xenografts.Anticancer Drugs. 1995;6:83–93.CrossRefGoogle Scholar
  14. 14.
    Chow DS, Gong L, Wolfe MD, Giovanella BC. Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin.Ann N Y Acad Sci. 2000;922:164–174.CrossRefGoogle Scholar
  15. 15.
    Williams J, Lansdown R, Sweitzer R, Romanowski M, LaBell R, Ramaswami R, et al. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors.J Control Release. 2003;91(1–2):167–172.CrossRefGoogle Scholar
  16. 16.
    Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as intracellular target of the anticancer drug camptothecin.Cancer Res. 1988;48:1722–1726.Google Scholar
  17. 17.
    Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.Cancer Res. 1989;49:5077–5082.Google Scholar
  18. 18.
    Mattern MR, Mong SM, Bartus HF, Mirabelli CK, Crooke ST, Johnson RK. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase-I in cultured L1210 cells.Cancer Res. 1987;47:1793–1798.Google Scholar
  19. 19.
    Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R, Potmesil M. Complete growth-inhibition of human cancer xenografts in nude-mice by treatment with 20-(S)-camptothecin.Cancer Res. 1991;51:3052–3055.Google Scholar
  20. 20.
    Pantazis P, Hinz HR, Mendoza JT, et al. Complete inhibition of growth followed by death of human-malignant melanoma-cells in vitro and regression of human-melanoma melanoma-cells in vitro and regression of human-melanoma xenografts in immunodeficient mice induced by camptothecins.Cancer Res. 1992;52:3980–3987.Google Scholar
  21. 21.
    Potmesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS, Giovanella BC, Growth-inhibition of human cancer metastases by camptothecins in newly developed xenograft models.Cancer Res. 1995;55:5637–5641.Google Scholar
  22. 22.
    Scott DO, Bindra DS, Stella VJ. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats.Pharm Res. 1993;10:1451–1457.CrossRefGoogle Scholar
  23. 23.
    Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase-I and biological-activity.J Med Chem. 1989;32:715–720.CrossRefGoogle Scholar
  24. 24.
    Gabizon A. Emerging role of liposomal drug carrier systems in cancer chemotherapy.J Liposome Res. 2003;13:17–20.CrossRefGoogle Scholar
  25. 25.
    Massing U, Fuxius S. Liposomal formulations of anticancer drugs: selectivity and effectiveness.Drug Resist Updat. 2000;3:171–177.CrossRefGoogle Scholar
  26. 26.
    Beckman®. Instructions for using the SW60 titanium rotor in class G H preparative ultracentrifuges. Spingo division of Backman Instruments, Inc. Palo Alto, California: 1978; LE-TB-002D.Google Scholar
  27. 27.
    Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.J Chromatogr B Biomed Sci Appl. 1997;691(1):161–171.CrossRefGoogle Scholar
  28. 28.
    Grohganz H, Ziroli V, Massing U, Brandl M. Quantitation of various phosphatidylcholines in liposomes by enzymatic assay.AAPS PharmSciTech. 2003;4:E63.CrossRefGoogle Scholar
  29. 29.
    Wako. Phospholipid B, enzymatic colorimetric method for the quantitative determination of phospholipids in serum and plasma. Code nr. 990-54009 E, Wako Chemicals GmbH: Neuss, Germany.Google Scholar
  30. 30.
    Frantzen C, Ingebrigtsen L, Skar M, Brandl M. Assessing the accuracy of routine photon correlation spectroscopy analysis of heterogeneous size distributions.AAPS PharmSciTech. 2003;4:E36.CrossRefGoogle Scholar
  31. 31.
    Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, et al. Development and characterization of a novel liposome-based formulation of SN-38.Int J Pharm. 2004;270(1–2):93–107.CrossRefGoogle Scholar
  32. 32.
    Zhang JA, Pawelchak J. Effect of pH, ionic strength and oxygen burden on the chemical stability of EPC/cholesterol liposomes under accelerated conditions. Part 1: Lipid hydrolysis.Eur J Pharm Biopharm. 2000;50:357–364.CrossRefGoogle Scholar
  33. 33.
    Grit M, Desmidt JH, Struijke A, Crommelin DJA. Hydrolysis of phosphatidylcholine in aqueous liposome dispersions.Int J Pharm. 1989;50:1–6.CrossRefGoogle Scholar
  34. 34.
    Perez-Soler R, Sugarman SM, Poirot KR, inventors. Lipid complexed topisomerase I inhibitors. US patent 5 834 012. November 10, 1998.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2004

Authors and Affiliations

  • Ann Mari Sætern
    • 1
  • Gøril Eide Flaten
    • 1
  • Martin Brandl
    • 1
  1. 1.Institute of Pharmacy, Department of Pharmaceutics and BiopharmaceuticsUniversity of TromsøTromsøNorway

Personalised recommendations